Alx Oncology Holdings (ALXO) Total Non-Current Liabilities (2019 - 2026)
Alx Oncology Holdings recorded quarterly Total Non-Current Liabilities of $23.5 million in Q1 2026, down 19.3% quarter-over-quarter from $29.1 million in Q4 2025, and down 12.98% year-over-year from $27.0 million in Q1 2025.
Alx Oncology Holdings' Total Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $23.5 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 12.98% year-over-year to $23.5 million; the TTM figure through Mar 2026 stood at $23.5 million (down 12.98% YoY), while the FY2025 annual figure was $29.1 million, up 3.99% from the prior year.
- Total Non-Current Liabilities came in at $23.5 million for Q1 2026 at Alx Oncology Holdings, down from $29.1 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $48.2 million in Q2 2024 to a low of $15.3 million in Q1 2022.
- A 5-year average of $32.4 million and a median of $29.1 million in 2025 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities soared 146.58% in 2022 and tumbled 46.4% in 2025, its largest moves.
- Alx Oncology Holdings' Total Non-Current Liabilities stood at $37.7 million in 2022, then gained by 21.02% to $45.6 million in 2023, then tumbled by 38.72% to $28.0 million in 2024, then rose by 3.99% to $29.1 million in 2025, then declined by 19.3% to $23.5 million in 2026.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $23.5 million, $29.1 million, and $33.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Alx Oncology Holdings | 189.80 Mn | 49.48 Mn | - | 23.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.47 Mn |
| Dec 31, 2025 | 29.09 Mn |
| Sep 30, 2025 | 33.49 Mn |
| Jun 30, 2025 | 25.85 Mn |
| Mar 31, 2025 | 26.97 Mn |
| Dec 31, 2024 | 27.97 Mn |
| Sep 30, 2024 | 42.18 Mn |
| Jun 30, 2024 | 48.22 Mn |
| Mar 31, 2024 | 41.93 Mn |
| Dec 31, 2023 | 45.64 Mn |
| Sep 30, 2023 | 44.72 Mn |
| Jun 30, 2023 | 27.08 Mn |
| Mar 31, 2023 | 31.34 Mn |
| Dec 31, 2022 | 37.71 Mn |
| Sep 30, 2022 | 25.24 Mn |
| Jun 30, 2022 | 23.95 Mn |
| Mar 31, 2022 | 15.31 Mn |
| Dec 31, 2021 | 15.30 Mn |
| Sep 30, 2021 | 12.49 Mn |
| Jun 30, 2021 | 13.98 Mn |
| Mar 31, 2021 | 14.13 Mn |
| Dec 31, 2020 | 6.20 Mn |
| Sep 30, 2020 | 10.39 Mn |
| Jun 30, 2020 | 11.65 Mn |
| Dec 31, 2019 | 10.41 Mn |